Format

Send to

Choose Destination
Arq Neuropsiquiatr. 2018 Oct;76(10):663-667. doi: 10.1590/0004-282X20180109.

Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison.

Author information

1
Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia/Neurocirurgia, São Paulo SP, Brasil.
2
Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Bioquímica, São Paulo SP, Brasil.
3
Hospital Israelita Albert Einstein, São Paulo SP, Brasil.

Abstract

OBJECTIVE:

The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing: pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders.

METHODS:

Patients were randomized into two groups: BT-A group (n = 18) and LLLT group (n = 18). Each patient kept three pain diaries: one before (baseline) (30 days), one during treatment (30 days) and one after the post-treatment phase (30 days). Repeated ANOVA plus the Bonferroni post-test, Student's t test, and factorial analysis were applied, and p < 0.05 was accepted as significant.

RESULTS:

Our data showed that both treatments were able to reduce headache days, acute medication intake and decrease the intensity of pain. Anxiety was reduced in the BT-A group, while sleep disturbance was reduced in the LLLT group.

CONCLUSION:

Our data showed that both treatments can be used to treat chronic migraine, without notable differences between them.

PMID:
30427505
DOI:
10.1590/0004-282X20180109
Free full text

Supplemental Content

Full text links

Icon for Scientific Electronic Library Online
Loading ...
Support Center